MedTrace Logo

SBRT for Oligometastatic Castration-Refractory Prostate Cancer

NCT02816983 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 89

Last updated 2022-08-25

No results posted yet for this study

Summary

Castration-resistant prostate cancer patients with rising prostatic specific antigen (PSA) are eligible for this study. 11C-Choline PET/CT will be used to identify metastatic lesions. Patients with \<=3 metastatic lesions will receive stereotactic body radiotherapy (SBRT) as definitive treatment. Blood draws will be taken to monitor the development of anti-prostate cancer immunity

Conditions

Interventions

RADIATION

SBRT

Sponsors & Collaborators

Principal Investigators

  • Sean S Park, MD, PhD · Mayo Clinic

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-03-31
Primary Completion
2022-01-20
Completion
2022-01-20

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02816983 on ClinicalTrials.gov